Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Italy fertility rate fell to new low of 1.14 in 2025 - 2UK, Canada, Germany, others condemn Israel's West Bank settlement plan
- 3RFK Jr. releases new dietary guidelines with emphasis on protein, full-fat dairy
- 4'Outrageous and illegal' : UNRWA slams Israel for cutting off its water, comms and electric in Gaza
- 5Warship sunk by British fleet, remains of sailor found after 225 years
- First Houthi launch toward Israel since war began triggers alerts across the Negev
- Best Augmented Simulation Ride: Which One Feels Generally Genuine?
- The Job of a Land Legal counselor in Property Exchanges
- 4 buzzy new TV shows to watch — plus the return of 'The Comeback,' 'Jury Duty' and more
- Forget 'Outer Banks.' These Gen Z-ers just want to watch 'M*A*S*H*' and 'Gilmore Girls.'
- Minute Maid’s frozen juice concentrate is ending after 80 years — and so is a certain kind of kitchen ritual
- Top 20 Wellbeing and Wellness Applications for a Sound Way of life
- Journeys That could only be described as epic: Delightful Voyage Lines All over the Planet
- The many ways that baking is winter therapy. With a delicious ending
